Skip to main content
. 2022 Mar 28;56(2):164–172. doi: 10.2478/raon-2022-0009

Figure 3.

Figure 3

Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.